Citigroup
MPLT icon

Citigroup’s MapLight Therapeutics MPLT Stock Holding History

Citigroup’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$603K Buy
59,173
+42,122
+247% +$790K ﹤0.01% 3649
2026
Q2 		$611K Buy
17,051
+16,091
+1,676% +$463K ﹤0.01% 3797
2026
Q1 		$19.5K Buy
960
+577
+151% +$10.3K ﹤0.01% 4828
2025
Q4 		$6.73K Buy
+383
New +$6.42K ﹤0.01% 5172

Other funds holding MPLT

Market Street Wealth Management Advisors
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 10.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Citigroup's MPLT Position: Q3 2026 in Review

Citigroup increased its MapLight Therapeutics (MPLT) stake by 247% in Q3 2026, buying an estimated $790K and bringing the position to 59,173 shares worth $603K. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

Citigroup first reported a position in MPLT in Q4 2025 and has held it in 4 quarters since. The position peaked at $611K in Q2 2026. 13 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • Citigroup held 59,173 shares of MapLight Therapeutics worth $603K as of Q3 2026.
  • Citigroup bought 42,122 MapLight Therapeutics shares in Q3 2026, an estimated $790K.
  • MapLight Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3649 holding.
  • Citigroup first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Citigroup's MapLight Therapeutics position peaked at $611K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.